

DAFTAR PUSTAKA

1. Engstrøm MJ, Opdahl S, Hagen AI, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. *Breast Cancer Res Treat.* 2013;1-11. doi:10.1007/s10549-013-2647-2
2. Engstrøm MJ, Opdahl S, Vatten LJ, Haugen OA, Bofin AM. Invasive lobular breast cancer: The prognostic impact of histopathological grade, E-cadherin and molecular subtypes. *Histopathology.* 2015;66(3):409-419. doi:10.1111/his.12572
3. Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Res.* 2010;12(4):207. doi:10.1186/bcr2607
4. Makki J. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clin Med Insights Pathol.* 2015;8:23-31. doi:10.4137/CPATH.S31563
5. Cho N. Molecular subtypes and imaging phenotypes of breast cancer. *Ultrason (Seoul, Korea).* 2016;35(4):281-288. doi:10.14366/usg.16030
6. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. *Biol Res.* 2017;50(1):33. doi:10.1186/s40659-017-0140-9
7. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. *J Adv Pharm Technol Res.* 2010;1(2):109-126.
8. Lakhani SR, Ellis IO, Schnitt SJ, et al. *WHO Classification of Tumours of the Breast.* Fourth Edi. (Lakhani SR, ed.). International Agency for Research on Cancer; 2012. doi:10.1097/PAS.0b013e318273b19b
9. Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World J Clin Oncol.* 2014;5(3):283-298. doi:10.5306/wjco.v5.i3.283
10. Mansfield CM. A review of the etiology of breast cancer. *J Natl Med Assoc.* 1993;85(3):217-221.
11. Libson S, Lippman M. A review of clinical aspects of breast cancer. *Int Rev Psychiatry.* 2014;26(1):4-15. doi:10.3109/09540261.2013.852971
12. Li J, Chen Z, Su K, Zeng J. Clinicopathological classification and traditional prognostic indicators of breast cancer. *Int J Clin Exp Pathol.* 2015;8(7):8500-8505.
13. Alnegheimish NA, Alshatwi RA, Alhefdhi RM, Arafah MM, AlRikabi AC, Husain S. Molecular subtypes of breast carcinoma in Saudi Arabia. A retrospective study. *Saudi Med J.* 2016;37(5):506-512. doi:10.15537/smj.2016.5.15000
14. Sotiriou C, Wirapati P, Loi S, et al. Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis. *JNCI J Natl Cancer Inst.* 2006;98(4):262-272. doi:10.1093/jnci/djj052
15. Schuh F, Biazús JV, Resetkova E, et al. Histopathological grading of breast ductal carcinoma In Situ: validation of a web-based survey through intra-observer reproducibility analysis. *Diagn Pathol.* 2015;10(1):93.

- doi:10.1186/s13000-015-0320-2
16. Chowdhury N. Histopathological and genomic grading provide complementary prognostic information in breast cancer: a study on publicly available datasets. *Patholog Res Int.* 2011;2011:890938.
doi:10.4061/2011/890938
17. Castellano I, Chiusa L, Vandone AM, et al. A simple and reproducible prognostic index in luminal ER-positive breast cancers. *Ann Oncol.* 2013;24(9):2292-2297. doi:10.1093/annonc/mdt183
18. Chen Y-Y, Tseng L-M, Yang C-F, Lien P-J, Hsu C-Y. Adjust cut-off values of immunohistochemistry models to predict risk of distant recurrence in invasive breast carcinoma patients. *J Chinese Med Assoc.* 2016;79(12):649-655. doi:10.1016/J.JCMA.2016.06.004
19. Yao K, Goldschmidt R, Turk M, et al. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. *Breast Cancer Res Treat.* 2015;154(1). doi:10.1007/s10549-015-3587-9